PlentiPlex™ MYD88
Waldenström's Macroglobulinemia (MYD88 L265P mutation)
ApprovedActive
Key Facts
Indication
Waldenström's Macroglobulinemia (MYD88 L265P mutation)
Phase
Approved
Status
Active
Company
About Pentabase
PentaBase is a private, revenue-generating diagnostics company leveraging its proprietary INA® (Intercalating Nucleic Acid) chemistry to create superior PCR-based assays for oncology. Its core technology enables highly sensitive and specific detection of genetic mutations and methylation patterns, which is critical for cancer diagnostics and monitoring. The company has a portfolio of commercial products, including CE-IVD kits for targets like MGMT and MYD88, and also operates a custom oligonucleotide design and manufacturing business. Headquartered in Copenhagen, Denmark, PentaBase serves a global market through a distributor network.
View full company profile